Literature DB >> 26099806

In vivo porcine lipopolysaccharide inflammation models to study immunomodulation of drugs.

H Wyns1, E Plessers2, P De Backer2, E Meyer2, S Croubels2.   

Abstract

Lipopolysaccharide (LPS), a structural part of the outer membrane of Gram-negative bacteria, is one of the most effective stimulators of the immune system and has been widely applied in pigs as an experimental model for bacterial infection. For this purpose, a variety of Escherichia coli serotypes, LPS doses, routes and duration of administration have been used. LPS administration induces the acute phase response (APR) and is associated with dramatic hemodynamic, clinical and behavioral changes in pigs. Pro-inflammatory cytokines, including tumor necrosis factor α (TNF-α), interleukin (IL)-1 and IL-6 are involved in the induction of the eicosanoid pathway and the hepatic production of acute phase proteins, including C-reactive protein (CRP), haptoglobin (Hp) and pig major acute phase protein (pig-MAP). Prostaglandin E2 (PGE2) and thromboxane A2 (TXA2) play a major role in the development of fever and pulmonary hypertension in LPS-challenged pigs, respectively. The LPS-induced APR can be modulated by drugs. Steroidal and nonsteroidal anti-inflammatory drugs ((N)SAIDs) possess anti-inflammatory, antipyretic and analgesic properties through (non)-selective central and peripheral cyclooxygenase (COX) inhibition. Antimicrobial drugs, especially macrolide antibiotics, which are commonly used in veterinary medicine for the treatment of bacterial respiratory diseases, have been recurrently reported to exert clinically important immunomodulatory effects in human and murine research. To investigate the influence of these drugs on the clinical response, production of pro-inflammatory cytokines, acute phase proteins (APP) and the course of the febrile response in pigs, in vivo LPS inflammation models can be applied. Yet, to date, in vivo research on the immunomodulatory properties of antimicrobial drugs in these models in pigs is largely lacking. This review provides acritical overview of the use of in vivo porcine E. coli LPS inflammation models for the study of the APR, as well as the potential immunomodulatory properties of anti-inflammatory and antimicrobial drugs in pigs.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  (N)SAIDs; Acute phase response; Antimicrobial drugs; Immunomodulation; LPS; Pigs

Mesh:

Substances:

Year:  2015        PMID: 26099806     DOI: 10.1016/j.vetimm.2015.06.001

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  31 in total

1.  Plasma kinetics and matrix residues of deoxynivalenol (DON) and zearalenone (ZEN) are altered in endotoxaemic pigs independent of LPS entry site.

Authors:  Erik Bannert; Tanja Tesch; Jeannette Kluess; Hana Valenta; Jana Frahm; Susanne Kersten; Stefan Kahlert; Lydia Renner; Hermann-Josef Rothkötter; Sven Dänicke
Journal:  Mycotoxin Res       Date:  2017-05-03       Impact factor: 3.833

2.  Dietary deoxynivalenol and oral lipopolysaccharide challenge differently affect intestinal innate immune response and barrier function in broiler chickens.

Authors:  Annegret Lucke; Josef Böhm; Qendrim Zebeli; Barbara U Metzler-Zebeli
Journal:  J Anim Sci       Date:  2018-12-03       Impact factor: 3.159

3.  Dietary Phytase- and Lactic Acid-Treated Cereals Caused Greater Taxonomic Adaptations than Functional Adaptations in the Cecal Metagenome of Growing Pigs.

Authors:  Jutamat Klinsoda; Julia Vötterl; Simone Koger; Barbara U Metzler-Zebeli
Journal:  Appl Environ Microbiol       Date:  2020-12-17       Impact factor: 4.792

4.  Interactions between metabolically active bacteria and host gene expression at the cecal mucosa in pigs of diverging feed efficiency.

Authors:  Barbara U Metzler-Zebeli; Peadar G Lawlor; Elizabeth Magowan; Qendrim Zebeli
Journal:  J Anim Sci       Date:  2018-06-04       Impact factor: 3.159

5.  Baicalin relieves inflammation stimulated by lipopolysaccharide via upregulating TUG1 in liver cells.

Authors:  Yanqiu Huang; Mengyan Sun; Xuefang Yang; Aiyu Ma; Yujie Ma; Aiying Zhao
Journal:  J Physiol Biochem       Date:  2019-08-08       Impact factor: 4.158

6.  In Vivo Studies of Drug BBB Transport: Translational Challenges and the Role of Brain Imaging.

Authors:  Stina Syvänen; Margareta Hammarlund-Udenaes; Irena Loryan
Journal:  Handb Exp Pharmacol       Date:  2022

7.  Inhibition of Lipopolysaccharide-Induced Inflammatory and Oxidative Responses by Trans-cinnamaldehyde in C2C12 Myoblasts.

Authors:  Cheol Park; Hyesook Lee; Suhyun Hong; Ilandarage Menu Neelaka Molagoda; Jin-Woo Jeong; Cheng-Yun Jin; Gi-Young Kim; Sung Hyun Choi; Sang Hoon Hong; Yung Hyun Choi
Journal:  Int J Med Sci       Date:  2021-04-23       Impact factor: 3.738

8.  Transcriptome analysis of porcine PBMCs reveals lipopolysaccharide-induced immunomodulatory responses and crosstalk of immune and glucocorticoid receptor signaling.

Authors:  Zhiwei Li; Nares Trakooljul; Frieder Hadlich; Siriluck Ponsuksili; Klaus Wimmers; Eduard Murani
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

9.  Nargenicin A1 attenuates lipopolysaccharide-induced inflammatory and oxidative response by blocking the NF-κB signaling pathway.

Authors:  Da Hye Kwon; Gi-Young Kim; Hee-Jae Cha; Suhkmann Kim; Heui-Soo Kim; Hye-Jin Hwang; Yung Hyun Choi
Journal:  EXCLI J       Date:  2021-05-28       Impact factor: 4.068

10.  Monitoring lung injury with particle flow rate in LPS- and COVID-19-induced ARDS.

Authors:  Martin Stenlo; Iran A N Silva; Snejana Hyllén; Deniz A Bölükbas; Anna Niroomand; Edgars Grins; Per Ederoth; Oskar Hallgren; Leif Pierre; Darcy E Wagner; Sandra Lindstedt
Journal:  Physiol Rep       Date:  2021-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.